Peptides for Menopause: An Evidence Table for Every Compound Marketed to Women Over 40

What the specialists recommend first

Before any peptide, the thing worth knowing is what the people who treat menopause for a living actually recommend, because the marketing rarely mentions it. The position is consistent across the major societies and has not changed: hormone therapy remains the most effective treatment for vasomotor symptoms — hot flushes and night sweats — and for the genitourinary syndrome of menopause, and for most healthy women under 60 and within ten years of their final period, the benefits outweigh the risks.¹

For women who cannot or prefer not to take it, two non-hormonal drugs are now approved in the United States specifically for moderate to severe vasomotor symptoms due to menopause, and neither is a peptide. Fezolinetant, a neurokinin 3 receptor antagonist, was approved in May 2023; its label carries a boxed warning for liver injury and requires liver tests before starting and during treatment.² Elinzanetant, which blocks both neurokinin 1 and 3 receptors, was approved in October 2025.^{3 4}

That is the comparison every peptide below is implicitly competing with: a first-line treatment with decades of trial data, and two approved alternatives with their own. None of the compounds in the table has been tested against any of them.

The label line that excludes this entire group

PT-141 is the peptide most often sold to women in midlife for low desire, usually under its research name rather than its brand. It is bremelanotide, and it is approved: Vyleesi, approved June 2019, for acquired, generalised hypoactive sexual desire disorder.⁵

Its label also contains a Limitations of Use section, and that section says, in the label's own words, that it is not indicated for the treatment of HSDD in postmenopausal women or in men, and not indicated to enhance sexual performance.⁶ The trials it was approved on enrolled premenopausal women. Selling it to women over 50 for menopausal low desire is not an off-label nuance; it is use in a population the label specifically carves out.

There is a second thing worth knowing even within the approved population. The two phase 3 trials showed statistically significant improvements in desire and related distress, and independent re-analyses published since have argued the effects were modest, that most protocol-listed outcomes went unreported while unlisted ones were published, and that discontinuation for adverse events was far higher on the drug.^{7 8} The original authors have replied.⁹ Our PT-141 entry carries both sides.

The evidence table

Every compound we have seen marketed to women over 40, what has been measured in this population, and the evidence grade from our encyclopedia. Grades reflect all human evidence for the compound, not only its menopause data.

Where the GLP-1 evidence actually stands

This is the one area where a peptide drug has genuine, growing evidence for a menopause-related problem, and it is also where the claims run ahead of it fastest.

What is established: GLP-1 receptor agonists produce weight loss and reduce central adiposity in menopausal and postmenopausal women, as a 2026 scoping review of this population found. The same review notes that effects on vasomotor symptoms and cardiovascular markers were reported in only a limited number of studies.¹¹

A 2026 position statement from the Spanish Menopause Society's young investigators group, developed from a literature search through April 2026, is more specific and more useful. It concludes that semaglutide provides the largest body of direct menopause-specific evidence among the incretin drugs, and that this evidence remains limited and largely observational. It also addresses a claim circulating in clinic marketing: that taking hormone therapy alongside a GLP-1 drug produces greater weight loss. The statement calls that association hypothesis-generating and says explicitly that it should not justify starting hormone therapy solely to augment weight loss.¹²

That is a careful, recent, expert position, and it is the opposite of how the combination is often sold.

The one trial that was actually done in this population

If you want a peptide with randomised evidence in postmenopausal women specifically, it is the one sold in supermarkets. A 12-month randomised placebo-controlled trial gave 131 postmenopausal women with age-related reduction in bone mineral density either 5 g a day of specific collagen peptides or placebo. Bone mineral density increased in the collagen group at the spine and femoral neck, and the bone formation marker P1NP rose in that group while the resorption marker CTX-1 rose in the control group.¹³

Two caveats belong with it, and both are in our collagen peptides review. The open-label four-year follow-up covered 31 of the original women and was uncontrolled, so it supports rather than confirms. And much of the collagen trial literature is funded or supplied by collagen manufacturers, which does not make the result false but does narrow what it supports: a specific preparation at a specific dose, not collagen in general.

Note also what the trial is not. It measured bone density, not fractures, over one year, in women with age-related low density rather than diagnosed osteoporosis. If you have osteoporosis, the drugs approved for it have fracture data; this does not.

What it means when a compound has no row

Most of the table says the same thing: no trial in this population. That deserves a sentence, because "no evidence" gets read two ways and only one of them is right.

It does not mean a compound has been shown not to work in menopausal women. It means nobody has looked. For BPC-157, CJC-1295, ipamorelin, epitalon, MOTS-c and NAD+, the human evidence is thin or absent in any population, so the absence of menopause data is not surprising — there is barely any data at all. The clinics writing about "peptides for perimenopause" are not drawing on a hidden literature; they are extrapolating from mechanism, from animal work, or from nothing.

That matters more in midlife than it might elsewhere, for a specific reason. Menopause produces a cluster of symptoms — sleep disruption, weight redistribution, low mood, joint aches, skin changes, low desire — that overlaps almost perfectly with what research peptides are marketed for. A compound sold for sleep, energy, body composition and skin will appear to address four menopause symptoms at once, without a single study in anyone going through it.

The question a weight drug raises specifically in this group

There is a reason the Spanish Menopause Society statement organises its guidance around body composition, cardiometabolic risk, musculoskeletal health, monitoring and hormone therapy rather than weight alone.¹² Weight loss from any cause takes lean mass with fat, and a postmenopausal woman is already losing bone: that is the premise of every osteoporosis-prevention recommendation in the menopause guidelines.¹

So the question that matters in this population is not only how much weight came off but what came off with it, and what is being done about it. That is a conversation about resistance training, protein intake and bone monitoring alongside the drug, not an argument against the drug. It is also the one part of the GLP-1 story that clinic marketing aimed at women over 40 almost never raises, despite being the part where this population differs most from the trial populations the headline figures come from.

It is worth noting what the collagen trial in this group did and did not show here as well. It measured bone mineral density over 12 months, not fractures, in women with age-related low density rather than diagnosed osteoporosis.¹³ Density is a surrogate. The drugs approved for osteoporosis have fracture data behind them; nothing on this page does.

Where these peptides come from, and why that matters here

Most of the compounds in the table are not sold in pharmacies as approved products. They reach women through two routes, and the difference between them is worth understanding before a first appointment.

The first is a clinic that prescribes a compounded preparation. Compounding is legal and long-established, but what may be compounded from bulk substances is governed by FDA lists, and several peptides marketed for midlife symptoms sit outside them. FDA's compounding advisory committee reviewed a group of these peptides in July 2026, and our regulatory tracker follows each compound's status, dated at the source, including what FDA has and has not decided since.

The second is a research-chemical vial bought online, which is where the peptide market as a whole gets most of its volume. Those products are not made under pharmacy oversight, and a purity certificate supplied by the seller frequently does not cover sterility — a distinction that matters for anything injected. Our verification guide and COA decoder set out what a certificate does and does not establish.

The practical point for a reader here is that the question "does this peptide work for menopause" and the question "is what I would be injecting what the label says" are separate, and both have to be answered. For most compounds in the table the first answer is "untested in this population", which makes the second one moot.

Questions worth asking a clinic

If a clinic recommends a peptide for menopausal symptoms, these are checkable rather than argumentative.

• Which trial was run in women like me? Not which mechanism, which trial, and in what population. For most of the compounds above, the honest answer is none.
• Is this approved, and for what? Approved for something else is not approved for this. Tesamorelin is approved for excess abdominal fat in adults with HIV, not for midlife weight gain.
• Why this before hormone therapy, or before the two approved non-hormonal drugs? If there is a reason — a contraindication, a preference, a prior adverse reaction — it should be stated and recorded.
• What would tell us it is not working, and when do we stop? A treatment with no stopping rule is a subscription.
• Who tested this vial? For compounded or research-sourced peptides, a purity certificate from the seller is not an independent test, and purity certificates frequently do not cover sterility. Our COA decoder covers what a certificate does and does not establish.

The short version

Hormone therapy is the most effective treatment for the symptoms most women come in with, and two non-hormonal drugs are now approved for hot flushes. Among peptides, GLP-1 drugs have real and growing evidence for midlife weight and central fat, with menopause-specific data that experts describe as limited and largely observational. Collagen peptides have one good 12-month bone trial in postmenopausal women. Bremelanotide is approved, and its label excludes postmenopausal women from its indication.

Everything else marketed under the heading of menopause peptides has no trial in menopausal women. That is not a reason to assume harm; it is a reason not to pay for certainty nobody has. Each compound's own entry in our encyclopedia sets out what has been measured, in whom, and what its regulatory and sport status is, dated at the source.

Frequently asked questions

What is the best peptide for menopause?

No peptide is approved for menopausal symptoms. The ones with real evidence in this population are GLP-1 drugs for weight and central fat, where menopause-specific data are limited and largely observational, and collagen peptides, which have one 12-month randomised bone-density trial in 131 postmenopausal women at 5 g a day.

Is PT-141 safe for postmenopausal women?

Its label answers a narrower question first: bremelanotide is not indicated for hypoactive sexual desire disorder in postmenopausal women. The trials enrolled premenopausal women, so there is no approved indication and no trial population that matches.

Do peptides help with menopause weight gain?

GLP-1 receptor agonists do produce weight loss and reduced central adiposity in menopausal and postmenopausal women. Growth hormone secretagogues marketed for 'menopause belly' — CJC-1295, ipamorelin, sermorelin — have no trial in this population at all.

Does taking HRT with a GLP-1 drug improve weight loss?

A 2026 Spanish Menopause Society position statement describes that association as hypothesis-generating and says it should not justify starting hormone therapy solely to augment weight loss.

What about oxytocin gel for vaginal dryness?

It has been tested. A 2023 systematic review and meta-analysis found no significant difference from control in dyspareunia, vaginal pH or histological evaluation of atrophy. Vaginal estrogen is the treatment menopause societies name for the genitourinary syndrome of menopause.

Are there non-hormonal options that are actually approved?

Yes, two, and neither is a peptide. Fezolinetant was approved in May 2023 and carries a boxed warning for liver injury requiring liver tests before and during treatment. Elinzanetant was approved in October 2025. Both are for moderate to severe vasomotor symptoms due to menopause.

Related on Grey Peptides

• Peptides and women's health: approved, studied, thin evidence
• PT-141 (bremelanotide)
• Collagen peptides: the trial evidence
• Semaglutide
• Peptide encyclopedia

Sources

1. Panay, N. et al. (2025). International Menopause Society (IMS) recommendations and key messages on women's midlife health and menopause. Climacteric, 28(6), 634-656. PMID: 41433054
2. Veozah (fezolinetant) prescribing information, Indications and Usage and boxed warning for hepatotoxicity (DailyMed SPL version 8, effective February 26, 2026; read October 1, 2026). Approved as NDA 216578 on May 12, 2023. FDA
3. Lynkuet (elinzanetant) prescribing information, Indications and Usage (DailyMed SPL version 10, effective June 16, 2026; read October 1, 2026). Approved as NDA 219469 on October 24, 2025. FDA
4. Lee, A. (2026). Elinzanetant: First Approval. Drugs, 86(1), 117-123. PMID: 41222830
5. Kingsberg, S. A. et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and Gynecology, 134(5), 899-908. PMID: 31599840
6. Vyleesi (bremelanotide) prescribing information, Indications and Usage including Limitations of Use (DailyMed SPL version 1, effective November 13, 2025; read October 1, 2026). Approved as NDA 210557 on June 21, 2019. FDA
7. Spielmans, G. I. (2021). Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder' in Women. Journal of Sex Research, 58(9), 1085-1105. PMID: 33678061
8. Spielmans, G. I. et al. (2024). Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. Journal of Sex Research. PMID: 36809187
9. Kingsberg, S. A. et al. (2021). Failure of a Meta-analysis: A Commentary on Glen Spielmans's 'Re-Analyzing Phase III Bremelanotide Trials'. Journal of Sex Research. PMID: 33835907
10. Farahat, R. A. et al. (2023). The efficacy of oxytocin gel in postmenopausal women with vaginal atrophy: an updated systematic review and meta-analysis. BMC Women's Health, 23(1), 494. PMID: 37716966
11. Graczyk, N. A. et al. (2026). Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review. Cureus, 18(1), e101693. PMID: 41704988
12. Sánchez-Prieto, M. et al. (2026). Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society. Maturitas, 213, 109101. PMID: 42664617
13. König, D. et al. (2018). Specific Collagen Peptides Improve Bone Mineral Density and Bone Markers in Postmenopausal Women - A Randomized Controlled Study. Nutrients, 10(1), 97. PMID: 29337906

This article is for education. It is not medical advice and it is not a recommendation to take or avoid any treatment. Decisions about menopause care, including hormone therapy, belong with a clinician who knows your history.